Beyfortus™ is a novel, long-acting RSV pre-exposure prophylaxis (pre-EP) monoclonal antibody developed by Sanofi and Genzyme. The vaccine was found to be safe and effective in preventing RSV infection in infants from 6 weeks to 5 months of age. The CDC's Advisory Committee on Immunization Practices (ACIP) voted unanimously to recommend routine use of Beyfortus™ for all infants in the United States.
Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment. Qunol® is a leading brand of nicotinamide riboside (NR) supplements, which are naturally produced in the body and play a role in cellular energy production.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5215
Published Date: Sep 04, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing demand for healthcare sector is the major factor driving the market growth.
The market size of mucopolysaccharidosis (MPS) treatment is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2023 â€“ 2035.
The major players in the market are Shire (now part of Takeda Pharmaceutical Company), Sanofi Genzyme, BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Regenxbio, Abeona Therapeutics, and others.
The hospitals segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
The market in the Asia Pacific region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.